As the battle for leadership position in the obesity-drug market intensifies, Novo Nordisk (NVO) rebranded itself as Novo. According to the company, the rebranding will give the company a “distinctive, recognizable and consistent way to connect with people, partners and other stakeholders around the world.”
At the same time, CEO Mike Doustdar is focused on making Novo “leaner and more competitive” as the company pushes to gain market share. A key step towards incremental market share is to speed-up drug discovery. For the same, Novo has announced a partnership with Anthropic. The collaboration aims to help Novo discover new medicines faster.
-copy-29e15046.jpeg?w=600)
